Validant Announces Acquisition of Clinical Outcomes Solutions
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Validant Announces Acquisition of Clinical Outcomes Solutions

Pharma Tech Outlook | Friday, June 04, 2021

COS was created in 2013 and has quickly risen to the top of the COA industry owing to its patient-centered approach and the development of the market’s most comprehensive collection of quantitative, scientific, and analytical skills.

FREMONT, CA: Validant, a leading global quality, compliance, and regulatory consulting group, announced the acquisition of Clinical Outcomes Solutions (COS), a global leader in Clinical Outcomes Assessments (COA).

COS was created in 2013 and has quickly risen to the top of the COA industry owing to its patient-centered approach and the development of the market’s most comprehensive collection of quantitative, scientific, and analytical skills. COA is a fast-growing segment of the health economics and outcomes research (HEOR) business that brings the perspective of patients into medication development.

Commenting on the announcement, Patrick Ronan, CEO of Validant, said: “We are once again delighted to welcome another best-in-class provider into the Validant family, further expanding the Groups service offering into HEOR and COA. Clinical Outcomes Solutions is a true category leader supporting customers across all facets of clinical outcomes research to improve patient care. We look forward to working together to better serve our combined customers.”

COS is headquartered in the United Kingdom, but it also has offices in Tucson, Arizona, and Chicago, Illinois, where it serves a diverse spectrum of biopharma clients globally. Validants’ acquisition of COS is another major step in its worldwide expansion strategy, which focuses on bringing together best-in-class regulatory-driven life science consultancies and investing in their growth.

Stacie Hudgens, CEO of COS, said: “The team and I have spent the last eight years developing innovative scientific methods to capture and communicate the patient voice. In Validant, we have found a company that shares our patient-centered beliefs, and we look forward to working together to grow our business, helping clients and patients around the world.”

Today’s announcement follows Validant’s acquisition of Greenleaf Health, a chief U.S. Food and Drug Administration (FDA) regulatory consulting firm in April 2021; December 2020 acquisition of Oriel STAT A MATRIX, a New Jersey-based global consultancy and training company; November 2020 acquisition of IDEC, a leading regulatory consultancy in Japan; and the purchase of DataRevive in 2019, a regulatory strategy and consultancy for global clients, based in Washington D.C.

Weekly Brief

Read Also